Research ArticleCancer

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

See allHide authors and affiliations

Science Translational Medicine  31 May 2017:
Vol. 9, Issue 392, eaal5148
DOI: 10.1126/scitranslmed.aal5148
PDF Container

Stay Connected to Science Translational Medicine

Navigate This Article